Can MiR-503 be used as a marker in diabetic patients with ischemic stroke?
Abstract Background Some microRNAs are involved in diabetes pathology and some are known to have role in stroke. MiR-503 causes endothelial dysfunction in diabetic patients, predisposing to ischemia. There has been no study evaluating Mir-503 level in diabetic patients with or without ischemic strok...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-04-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12902-019-0371-6 |
| _version_ | 1818922876538978304 |
|---|---|
| author | Saba Sheikhbahaei Danesh Manizheh Saadatnia Mohammad Tajaddini Mohamad Hasan Nazemian Saman Rafiee Laleh Motieian Mahsa Amoushahi Khouzani Sanaz Haghjooy Javanmard Shaghayegh |
| author_facet | Saba Sheikhbahaei Danesh Manizheh Saadatnia Mohammad Tajaddini Mohamad Hasan Nazemian Saman Rafiee Laleh Motieian Mahsa Amoushahi Khouzani Sanaz Haghjooy Javanmard Shaghayegh |
| author_sort | Saba Sheikhbahaei |
| collection | DOAJ |
| description | Abstract Background Some microRNAs are involved in diabetes pathology and some are known to have role in stroke. MiR-503 causes endothelial dysfunction in diabetic patients, predisposing to ischemia. There has been no study evaluating Mir-503 level in diabetic patients with or without ischemic stroke. Methods We designed a cross-sectional study to assess and compare serum level of MiR-503 in 4 groups of diabetic patients with ischemic stroke (I), non-diabetic patients with stroke (II), diabetic patients (III), and healthy controls (IV) in acute phase and 3 months later. Results Our data analysis showed that mean relative expression of MiR-503 in group (I) was significantly higher than 3 other groups (p < 0.05). The level of miR-503 was related to the patients’ fasting blood glucose, Cholesterol level, NIHSS score and acute–phase modified Rankin Scale (mRS) (r = 0.49, p = 0.001, r = 0.5, p = 0.009, r = 0.45, p = 0.009, r = 0.48, p = 0.003, CI = 95%). Relative expression of miR in patients with mRS ≤ 2 (good outcome) was lower than in patients with mRS > 2 (poor outcome) (p = 0.008). After 3 months, level of miR decreased significantly only in group (I) (p = 0.002). Mean relative expression of miR-503 in chronic phase was not significantly different among groups (p-value> 0.05). There was no relation between miRNA level and mRS in chronic phase. Conclusion Hyperglycemia and ischemia together raise the level of MiR-503 acutely but it does not remain at high level after 3 months. Although higher miR was related to more disability in acute phase, it does not affect long-term outcome in ischemic patients. As MiR-503 is stable enough in blood it can be used as a potential diagnostic marker of an ischemic stroke in diabetic patient. Its level also is an indicator of stroke severity and patients’ short-term outcome. It is recommended to study whether antagomiR-503 is a new therapeutic agent reducing the severity of and disability due to stroke. |
| first_indexed | 2024-12-20T02:00:30Z |
| format | Article |
| id | doaj.art-9cafceb926854de6ba78c594d9bcf3b2 |
| institution | Directory Open Access Journal |
| issn | 1472-6823 |
| language | English |
| last_indexed | 2024-12-20T02:00:30Z |
| publishDate | 2019-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj.art-9cafceb926854de6ba78c594d9bcf3b22022-12-21T19:57:21ZengBMCBMC Endocrine Disorders1472-68232019-04-011911710.1186/s12902-019-0371-6Can MiR-503 be used as a marker in diabetic patients with ischemic stroke?Saba Sheikhbahaei0Danesh Manizheh1Saadatnia Mohammad2Tajaddini Mohamad Hasan3Nazemian Saman4Rafiee Laleh5Motieian Mahsa6Amoushahi Khouzani Sanaz7Haghjooy Javanmard Shaghayegh8Acquired Immunodeficiency Research Center, Isfahan University of Medical SciencesStudent Research Committee, Isfahan University of Medical SciencesIsfahan Neurosciences Research Center, Isfahan University of Medical SciencesApplied Physiology Research Center, Isfahan University of Medical SciencesMashhad University of Medical SciencesApplied Physiology Research Center, Isfahan University of Medical SciencesIsfahan University of Medical SciencesStudent Research Committee, Isfahan University of Medical SciencesApplied Physiology Research Center, Isfahan University of Medical SciencesAbstract Background Some microRNAs are involved in diabetes pathology and some are known to have role in stroke. MiR-503 causes endothelial dysfunction in diabetic patients, predisposing to ischemia. There has been no study evaluating Mir-503 level in diabetic patients with or without ischemic stroke. Methods We designed a cross-sectional study to assess and compare serum level of MiR-503 in 4 groups of diabetic patients with ischemic stroke (I), non-diabetic patients with stroke (II), diabetic patients (III), and healthy controls (IV) in acute phase and 3 months later. Results Our data analysis showed that mean relative expression of MiR-503 in group (I) was significantly higher than 3 other groups (p < 0.05). The level of miR-503 was related to the patients’ fasting blood glucose, Cholesterol level, NIHSS score and acute–phase modified Rankin Scale (mRS) (r = 0.49, p = 0.001, r = 0.5, p = 0.009, r = 0.45, p = 0.009, r = 0.48, p = 0.003, CI = 95%). Relative expression of miR in patients with mRS ≤ 2 (good outcome) was lower than in patients with mRS > 2 (poor outcome) (p = 0.008). After 3 months, level of miR decreased significantly only in group (I) (p = 0.002). Mean relative expression of miR-503 in chronic phase was not significantly different among groups (p-value> 0.05). There was no relation between miRNA level and mRS in chronic phase. Conclusion Hyperglycemia and ischemia together raise the level of MiR-503 acutely but it does not remain at high level after 3 months. Although higher miR was related to more disability in acute phase, it does not affect long-term outcome in ischemic patients. As MiR-503 is stable enough in blood it can be used as a potential diagnostic marker of an ischemic stroke in diabetic patient. Its level also is an indicator of stroke severity and patients’ short-term outcome. It is recommended to study whether antagomiR-503 is a new therapeutic agent reducing the severity of and disability due to stroke.http://link.springer.com/article/10.1186/s12902-019-0371-6miR-503MicroRNAMiRNAIschemic strokeDiabetesHyperglycemia |
| spellingShingle | Saba Sheikhbahaei Danesh Manizheh Saadatnia Mohammad Tajaddini Mohamad Hasan Nazemian Saman Rafiee Laleh Motieian Mahsa Amoushahi Khouzani Sanaz Haghjooy Javanmard Shaghayegh Can MiR-503 be used as a marker in diabetic patients with ischemic stroke? BMC Endocrine Disorders miR-503 MicroRNA MiRNA Ischemic stroke Diabetes Hyperglycemia |
| title | Can MiR-503 be used as a marker in diabetic patients with ischemic stroke? |
| title_full | Can MiR-503 be used as a marker in diabetic patients with ischemic stroke? |
| title_fullStr | Can MiR-503 be used as a marker in diabetic patients with ischemic stroke? |
| title_full_unstemmed | Can MiR-503 be used as a marker in diabetic patients with ischemic stroke? |
| title_short | Can MiR-503 be used as a marker in diabetic patients with ischemic stroke? |
| title_sort | can mir 503 be used as a marker in diabetic patients with ischemic stroke |
| topic | miR-503 MicroRNA MiRNA Ischemic stroke Diabetes Hyperglycemia |
| url | http://link.springer.com/article/10.1186/s12902-019-0371-6 |
| work_keys_str_mv | AT sabasheikhbahaei canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT daneshmanizheh canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT saadatniamohammad canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT tajaddinimohamadhasan canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT nazemiansaman canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT rafieelaleh canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT motieianmahsa canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT amoushahikhouzanisanaz canmir503beusedasamarkerindiabeticpatientswithischemicstroke AT haghjooyjavanmardshaghayegh canmir503beusedasamarkerindiabeticpatientswithischemicstroke |